Tonix Pharmaceuticals (TNXP) Expected to Post Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) is anticipated to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($2.6425) per share and revenue of $7.7220 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 8:30 AM ET.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, May 11th. The company reported ($2.93) EPS for the quarter, missing the consensus estimate of ($2.54) by ($0.39). The company had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $6.12 million. Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. On average, analysts expect Tonix Pharmaceuticals to post $-10 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock traded up $0.10 during mid-day trading on Monday, hitting $10.11. 45,834 shares of the stock were exchanged, compared to its average volume of 457,349. The stock’s fifty day simple moving average is $11.73 and its two-hundred day simple moving average is $13.64. Tonix Pharmaceuticals has a 12-month low of $9.40 and a 12-month high of $69.97. The stock has a market capitalization of $161.12 million, a price-to-earnings ratio of -0.71 and a beta of 1.69.

Wall Street Analysts Forecast Growth

TNXP has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. TD Cowen raised Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. Wall Street Zen downgraded Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Finally, Raymond James Financial started coverage on Tonix Pharmaceuticals in a report on Wednesday, June 24th. They issued a “strong-buy” rating and a $26.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Tonix Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $24.00.

Insiders Place Their Bets

In other news, Director Richard Newcomb Stillwell purchased 5,000 shares of the company’s stock in a transaction on Monday, June 8th. The stock was bought at an average cost of $11.65 per share, for a total transaction of $58,250.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $58,250. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Seth Lederman acquired 5,000 shares of Tonix Pharmaceuticals stock in a transaction dated Tuesday, June 9th. The stock was purchased at an average cost of $11.79 per share, for a total transaction of $58,950.00. Following the completion of the purchase, the chief executive officer directly owned 9,005 shares in the company, valued at approximately $106,168.95. This represents a 124.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 11,415 shares of company stock worth $132,128. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Large investors have recently made changes to their positions in the business. Man Group plc purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $288,000. Engineers Gate Manager LP raised its position in Tonix Pharmaceuticals by 63.7% in the fourth quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock valued at $223,000 after purchasing an additional 5,550 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth about $2,895,000. AQR Capital Management LLC purchased a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth about $313,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $171,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.